We reported previously that fusogenic liposome (FL) introduced antigen protein encapsulated in the liposome directly into the cytoplasm of the antigen presenting cells, and that it induced immune responses. In the present study, we encapsulated TAX38-46, an HTLV-I derived protein and an antigen peptide model, into FL. The ability to induce effective cytotoxic T lymphocytes (CTL) responses in immunized mice was evaluated. Results showed FL could induce CTL response effectively and suggested that FL is a potential peptide vaccine carrier.
Induction of cytotoxic T lymphocytes (CTL) that kill tumor cells is a critical role of immunotherapeutic agents for cancer. Most cancer vaccine strategies have focused on induction of CTL and various approaches, including DNA, virus vector or peptide vaccine, have been tested. 1) In general, the advantages of a peptide vaccine are the induction of CTL by the epitope and the safety, stability and simplicity of peptide production. However, peptides by themselves are rather weak immunogens. Peptides usually require the addition of an adjuvant for inducing immunogenicity, and recently, incomplete Freund's adjuvant (IFA) has been widely used as a vaccine adjuvant in clinical research.
2) However, IFA is only useful for inducing humoral immunity and thus it does not induce effective cell-mediated immune responses. In contrast, complete Freund's adjuvant (CFA) is used for CTL induction, although it cannot be applied clinically due to serious side effects, such as inflammation. 3) To induce cell-mediated immune responses, a peptide must be delivered through the cytoplasm to the MHC class I processing pathway. However, peptides are unable to pass through the cytoplasm alone.
4) Therefore, we hypothesized that a vaccine carrier is required, which can deliver antigens into the cytoplasm and which exhibits adjuvant activity. We reported previously that fusogenic liposome (FL) introduces antigen protein encapsulated in the liposome directly into the cytoplasm, and that it can induce effective immune responses. [5] [6] [7] FL is a fusion liposome in which proliferating ability is inactivated, but which retains its cell membrane fusing ability. Therefore, FL can deliver encapsulated molecules into cells. Furthermore, FL possesses immune stimulating activity. 5) In this context, we considered FL as an ideal peptide vaccine carrier.
In the present study, we chose the TAX protein epitope (TAX 38-46; H-2D kϪ restricted epitope in TAX, amino acid residues 38-46, sequence ARLHRHALL. 10) ), which is an immunodominant target antigen derived from the human T-cell leukemia virus type 1 (HTLV-I), as a model peptide. HTLV-I, a retro virus, is known to cause Adult T-cell leukemia (ATL). 8) ATL is characterized by poor prognosis after chemotherapy and no effective therapy exists. Immunotherapy, which can induce strong anti HTLV-I CTL, has been proposed as an optimal approach to ATL treatment. 9) However, an effective immunotherapeutic approach has not been developed to date.
MATERIALS AND METHODS
Cells and Animals L929 cells were cultured with RPMI-1640 containing with 10% fetal calf serum (FCS). Female C3H mice were purchased from Nippon SLC (Kyoto, Japan) and used at 6 weeks-old stage.
Fusogenic Liposome Encapsulated TAX 38-46 TAX 38-46 and FITC conjugated TAX 38-46 were purchased from SIGMA (Japan). FL was prepared as described previously.
5-7)
Briefly, lipid mixture (L-a-dimyristoyl phosphatidic acid/ phosphatidylcholine/cholesterol in molar ratio of 1 : 4 : 5) was hydrated with phosphate buffered saline (PBS) or PBS containing TAX 38-46 or FITC conjugated TAX 38-46. Peptides containing liposome was prepared from these hydrated mixture by using a hand-held extruder with two layers of cellulose acetate membranes (pore size, 800 nm in diameter) (ADVANTEC, Osaka, Japan), and washed with PBS by centrifugation (20000 rpm, 40 min, 4°C) in order to remove free peptides. These liposomes were mixed with UV-inactivated Sendai virus and incubated at 37°C for 2 h with shaking. FL was purified by sucrose gradient centrifugation (24000 rpm, 2 h, 4°C). The diameter of FL was detected by using ZETA-SIZER 3000HS (Malvern, U.K. TAX38-46), or TAX38-46 encapsulated in FL (contains 30 mg TAX38-46) diluted to in total were injected into back of C3H mice (i.d.), respectively. Mice were immunized once a week for three weeks, and the spleen was harvested 9 d after the last immunization. Splenocytes were mixed with mitomycin C (MMC) treated TAX38-46 pulsed L929 for 5 d, and CTL assay was determined as follows. L929 cells (5ϫ10 6 ) were pulsed with TAX 38-46 (positive targets) for 1 h at 37°C or not (negative targets), and labeled with 200 mCi of 51 Cr for 2 h at 37°C. Splenocytes were incubated with target cells (positive or negative targets) for 2 h at 37°C. CTL activity was determined by measuring 51 Cr levels in the supernatants using a gamma counter. The specific lysis was determined as follows: percentage of specific lysisϭ (percentage of positive target lysis)Ϫ(percentage of negative target lysis).
RESULTS AND DISCUSSION
We prepared the FL encapusulating TAX 38-46. The diameter of FL was 880.1Ϯ9.5 nm. We calculated the concentrarion of peptide in FL using FITC conjugated TAX38-46. One milliliter of FL suspension at OD 540 of 1.0 contained 29.8 mg of TAX 38-46. FL encapsulating TAX 38-46 was immunized with 100 ml at OD 540 of 10.0. Figure 1 demonstrates that the induction of TAX-specific CTL occurred only in response to TAX38-46-FL. CTL induction could not be detected in the TAX38-46-CFA administered group, in the TAX38-46 group, or in the empty FL group. Likewise, there was no CTL response in the group immunized with the mixture of TAX 38-46 and empty FL (data not shown). Previous reports have demonstrated that FL can deliver peptide directly into cytoplasm and that it possesses immune stimulating ability.
In a future study, we will investigate the control of peptide distribution in the cytoplasm and attempt to induce a stronger CTL response. Peptides that target the endoplasmic reticulum (ER) are able to induce stronger CTL responses because MHC class I molecules are expressed on the ER membrane. [11] [12] [13] However, because FL cannot control peptide distribution in the cytoplasm, we were unable to target the ER specifically. Therefore, the use of both FL and ER targeting sequences will more effectively induce CTL. 
